A Phase I/Ⅱ Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of MBS303 in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs MBS 303 (Primary) ; MIL-62 (Primary)
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Beijing Mabworks Biotech
- 20 Nov 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Nov 2025.
- 09 Aug 2023 Status changed from not yet recruiting to recruiting.
- 12 Apr 2023 New trial record